Ultragenyx bags FDA priority review for groundbreaking GSDIa gene therapy

If approved, DTX401 would be the first treatment to address the disease at its root cause

Siegfried delivers strong 2025 performance, bolsters US expansion

Net sales reached CHF 1,327.8 million, up 2.6% year-on-year in Swiss francs, or 4.3% at constant exchange rates

Lupin receives European Commission approval for biosimilar Ranibizumab

BMS reports positive Phase 2 data for Luspatercept in alpha-thalassemia

Both non-transfusion-dependent and transfusion dependent cohorts met their respective primary and secondary endpoints

Maverick Simulation Solutions unveils ‘SIDDH’, India’s next-gen critical care patient simulator

Our vision is to position India not just as a consumer of advanced simulation technologies but as a creator and exporter of them

Lilly’s Retevmo shows breakthrough results in early-stage lung cancer trial

The drug’s safety profile in LIBRETTO-432 aligned with previous selpercatinib studies, showing no unexpected concerns

FDA accepts Teva’s NDA for long-acting schizophrenia injection

If approved, TEV-'749 could help address a significant unmet need in available schizophrenia treatment options by addressing the lack of viable long-acting olanzapine formulations

Johnson & Johnson bags FDA nod for monthly RYBREVANT FASPRO dosing in advanced lung cancer

This approval builds on the recent transformation RYBREVANT FASPRO brought to lung cancer care

BioAsia 2026 cements Telangana’s global leadership in TechBio and life sciences

40+ most innovative startups with disruptive contributions across MedTech, Medical Devices, BioPharma, Cell and Gene Therapy, AI and ML, Nutraceuticals, and Biomarkers exhibited their cutting-edge solutions

Catalent and S.Biomedics join forces to advance groundbreaking Parkinson’s therapy

TED?A9 is part of S.Biomedics’ expanding pipeline of stem-cell-based therapies, developed using the company’s proprietary targeted embryonic stem cell differentiation platform